Genus plc (LSE: GNS), the world-leading animal genetics company headquartered in Basingstoke, has announced the appointment of Sharmila Nebhrajani to its Board as a Non-Executive Director, effective 1 January 2027. The appointment follows an extensive search process conducted with the assistance of an external search agency. Ms Nebhrajani brings broad experience across public health, medical research, government policy and commercial sectors, adding significant non-executive depth to the Genus Board as the company continues to operate across more than seventy-five countries under its ABS and PIC trademarks.

Key Points

  • Genus plc (GNS) — world-leading animal genetics company listed on the London Stock Exchange
  • Sharmila Nebhrajani appointed Non-Executive Director with effect from 1 January 2027
  • Remuneration details will be disclosed in full in the Company's 2027 Directors' Remuneration Report
  • Investors should watch for further Board composition updates and any committee role assigned to Ms Nebhrajani

Sharmila Nebhrajani's Background and Qualifications for the Genus Board Role

Ms Nebhrajani is a Chartered Accountant holding an MA in Physiological Sciences from Oxford University. Her career spans senior roles in public health and medical research, working with government bodies, medical charities, and pharmaceutical industry partners, as well as international policy dialogue involving multilateral agencies, NGOs, and senior policymakers. This combination of scientific literacy and commercial governance experience aligns closely with Genus's business model, which applies biotechnology to improve animal genetics across the dairy, beef, and pork food production sectors, selling products including semen, embryos, and breeding animals with superior genetics.

Nebhrajani's Existing Non-Executive Portfolio Across FTSE-Listed Companies

At the time of the announcement, Ms Nebhrajani holds a range of prominent non-executive positions, including remuneration committee chair at ITV plc, senior independent director and audit committee chair at Halma plc, and non-executive director of Essentra plc. She is also Chair of the National Institute for Health and Care Excellence. The announcement notes she will step down from the Board of Severn Trent plc on 30 November 2026, ahead of joining Genus. She was previously a non-executive director of Coutts & Co. Her audit and remuneration committee experience across listed companies is notably relevant to Genus's governance requirements.

Genus's Global Operations and Strategic Context for the Board Appointment

Genus operates in over twenty-five countries on six continents, with research laboratories in Madison, Wisconsin, USA, and its global sales spanning more than seventy-five countries. The Group's competitive advantage rests on proprietary breeding animal lines, biotechnology platforms, and an extensive global supply chain under the ABS and PIC trademarks. The company's customers use Genus genetics to produce offspring with greater production efficiency and quality, supplying global dairy and meat supply chains. Chair Iain Ferguson stated in the announcement that Ms Nebhrajani brings "a broad range of commercial, strategic and scientific experience and knowledge" to the Board.

Remuneration Disclosure and Regulatory Compliance for the Appointment

The announcement confirms the appointment was made in accordance with Listing Rule 6.4.6R, with the company noting there are no matters to disclose under Listing Rule 6.4.8R (2)–(6). Full details of any payments to be made to Ms Nebhrajani will be disclosed in the Company's 2027 Directors' Remuneration Report, and any such terms will be consistent with the Company's approved Directors' Remuneration Policy. The company did not disclose the specific remuneration figure in the announcement. Investors monitoring Board governance at Genus will find the formal disclosure in the upcoming annual remuneration report.